Sign in
ADYX Stock Price, Chart, Stats & News
Adynxx, Inc.
Save
Adynxx, Inc. (ADYX) does not currently pay a dividend.
581
Market cap
–
Current P/E
–
Forward P/E
ADYX chart
About
Health care
Sector
Biotechnology
Industry
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain.
Similar securities
Based on sector and market capitalization
Report issue